THE ANTICANCER DRUG "HD88"
DRUG DESCRIPTION
For more than 30 years the drug HD88 has been applied to thousands of patients with different types of cancer. Very good results shown by HD88 permit this drug to be recommended for treatment of cancer (neoplasms).
HD88 is applied strictly intredermally 0.1ml on the volar side of the forearm, like Mantoux. The treatment follows certain therapeutic scheme on time intervals of one to several months.
The medicine reaches satisfactory concentrations in the patient’s body generally after the second/third injection and this is the period after which one can expect the curative effect of HD88: decrease in the concomitant symptoms and after some more injections - regression of the cancer cells. These effects are long-lasting and durable – for months and years.
AMONG THE MAIN ADVANTAGES OF HD88 ARE:
1. Powerful immunostimulating effect
2. High effectiveness against different types of neoplasms.
3. High effectiveness against the cancer metastases.
4. Harmless and safety
5. No side effects have been observed
HD88 has proven anticancer activity and showed to be effective in many types of solid neoplasms (tumors) – carcinomas, sarcomas, mesotheliomas, germinomas and gliomas.
The effect of HD88 is expressed in stopping the tumor growth, decreasing the size of the tumor and/or metastases up to their disappearing.
BEST RESULTS HAVE BEEN OBSERVED WITH:
• Breast cancer
• Cancer of the large bowel (colon & rectum)
• Lung cancer
• Cancer of the uterus (Endometrial cancer)
• Ovarian cancer
• Cancer of the stomach
• Urinary bladder cancer
• Pancreatic cancer
• Brain tumors
• Cancer of the larynx
• Prostate cancer
• Skin cancer (especially Melanoma malignum)
as well as Kidney cancer, Liver cancer, Testicular cancer, Thyroid cancer, Metastatic tumors of unknown primary origin etc.
HD88 has not been fully and satisfactory studied in lymphomas, leukaemias, leucosis and ìultiple myeloma.
INDICATIONS & ACTION:
1. HD88 is highly effective in preventing relapses and metastases formation of malignant tumors after surgical treatment, as well as after radiation therapy and/or chemotherapy.
2. Treatment with HD88 is most effective after radical or partial surgical removal of the tumor, but has also demonstrated excellent results in many inoperable tumors.
3. The drug is an optimal alternative for treatment of most type of cancers that are not suitable or impossible for application of surgical operation, radiation therapy and/or chemotherapy.
4. HD88 has powerful immunostimulating effect.
5. The drug is used as an immunotherapy of benign tumors, containing glandular tissues (adenomas, glandular polyps) and fibrotic tissues (fibromas, fibroadenomas, fibromyomas) as well as for preventing malignancy of benign tumors.
6. Treatment of the mastopathy, endometriosis and myoma of the uterus in women.
7. Treatment of the benign prostatic hyperplasia.
8. Appropriate in those cases where the cancer is not visible but the tumor markers are in higher than normal levels (elevated levels of one or more of the following tumor markers: CA 15-3, CA 19-9, CA 72-4, CA 125, CEA, SCC, PSA, PAP, NSE etc.)
CONTRAINDICATIONS:
HD88 is absolutely harmless. The drug does not render any toxic effect in normal cells of the human organism; has no mutagenic and teratogenic effect and does not contain any tumor cells.
There are no absolute contraindications for HD88 treatment. The drug is not recommended for use: during pregnancy; during 3-4 days after acute infectious diseases; during the activation of the chronic diseases; in case of potent allergic reaction to the drug during the previous administration.
As a matter of principle HD88 is not administrated during radiation therapy and/or chemotherapy, but has a powerful effect when applied 10-15 days after their termination.
SIDE EFFECTS:
Treatment with HD88 has no side effects, with the exception of mild reversible redness around the application spot in less than 1 % of the cases.
The patient should be under doctor's observation during the administration of the drug.
Treatment with HD88 is administered in three centers (cities) in Bulgaria – Sofia, Plovdiv and Varna (see under “Contacts ”).